ADAC names interim CFO
As it struggles to cope with accounting irregularities, ADAC Laboratories of Milpitas, CA, announced a replacement for its chief financial officer, Andre Simone. Effective this month, Robert Bunje will serve as ADAC’s interim CFO while the
As it struggles to cope with accounting irregularities, ADAC Laboratories of Milpitas, CA, announced a replacement for its chief financial officer, Andre Simone. Effective this month, Robert Bunje will serve as ADACs interim CFO while the company searches for a permanent replacement. Bunje brings to the position 25 years of experience as a partner at Deloitte & Touche, where he served before his retirement in 1994 as managing director for the companys international merger and acquisition services division. Simone will continue to serve as a consultant to ADAC, the company said.
The news of Simones departure from the CFO post comes in the midst of ADACs struggle with accounting problems: Late last year, ADAC announced that it would have to restate revenues for the past three years (SCAN 5/26/99). On May 19, just days before the company announced Bunjes appointment to the interim CFO post, ADAC reported that it would delay the release of its second quarter (end-April) financial results as it determines whether to establish additional reserves.
In other ADAC news, former chief executive David Lowe severed his last ties with the company when he relinquished his seat on the vendors board late last month. Lowe helped transform ADAC from a struggling company into the market-share leader in nuclear medicine. He resigned his board seat to devote more time to the private investment firm he co-founded.
© 1999 Miller Freeman, Inc.All rights reserved.
Considering Breast- and Lesion-Level Assessments with Mammography AI: What New Research Reveals
June 27th 2025While there was a decline of AUC for mammography AI software from breast-level assessments to lesion-level evaluation, the authors of a new study, involving 1,200 women, found that AI offered over a seven percent higher AUC for lesion-level interpretation in comparison to unassisted expert readers.
SNMMI: Can 18F-Fluciclovine PET/CT Bolster Detection of PCa Recurrence in the Prostate Bed?
June 24th 2025In an ongoing prospective study of patients with biochemical recurrence of PCa and an initial negative PSMA PET/CT, preliminary findings revealed positive 18F-fluciclovine PET/CT scans in over 54 percent of the cohort, according to a recent poster presentation at the SNMMI conference.
